div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036fdocumentsesreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036fdocumentsesreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036fdocumentsesreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036fdocumentsesreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 5button div class=trans-image amp-img class=trans-thumb alt=Page 5: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör...